Colorectal Liver Metastases
Conditions
Keywords
neoadjuvant chemotherapy, bevacizumab
Brief summary
Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.
Detailed description
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is typically used in combination with other chemotherapeutic agents such as oxaliplatin, irinotecan, leucovorin and 5-fluorouracil (5-FU) for treatment of patients with CRLM. The objective of this study was to assess the impact of neoadjuvant bevacizumab on clinical outcome after hepatectomy of colorectal liver metastases (CRLM). Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients will be distributed in two groups, either with or without bevacicumab. Outcome parameters are mortality, complications, hospital stay and ICU stay. To increase the power of the study the total number of patients will be increased by adding patients from other centers. Results will be adjusted for the propensity of developing complications.
Interventions
DRUGbevacizumab
Neoadjuvant chemotherapy with bevacizumab
Sponsors
University of Zurich
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with neoadjuvant chemotherapy prior to liver resection
Exclusion criteria
* Patients without neoadjuvant chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall complications | postoperative |
Secondary
| Measure | Time frame |
|---|---|
| specific complications such as liver insufficiency, length of hospital stay | postoperative |
Countries
France, Spain, Switzerland
Outcome results
None listed